Eli Lilly said the increase brings the UK price in line with other European markets, though NHS availability will be ...

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterised by the accumulation of scar tissue in the ...

Sanofi's Tzield is now the first and only disease-modifying therapy to be approved for type 1 diabetes (T1D) in the UK.

The White House has blamed the Biden administration for failing to advance domestic production or fill the reserve.

Ovarian cancer is one of the most challenging malignancies in oncology. Despite advances in diagnosis and treatment, it is ...

Amphastar has signed an exclusive license agreement with Anji for the development, production, use and commercialisation of 3 ...

Basilea has acquired the global rights for Venatorx Pharmaceuticals’ ceftibuten-ledaborbactam etzadroxil, an antibiotic being ...

Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for GPCR ...

Fosun Pharma Industrial has entered a licence agreement to grant ex-China rights for its respiratory drug, XH-S004, to ...

This podcast tackles how pharma can drive better commercial packaging collaborations during the transition from clinical to ...

Despite posting record Q2 growth for its blockbuster weight loss and diabetes drug tirzepatide, Eli Lilly is facing legal ...

With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the US EoE market ...